NAFLD与肝细胞恶性转化相关研究新进展*

doi:10.3969/j.issn.1672-5069.2022.02.002

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (2): 157-160.doi: 10.3969/j.issn.1672-5069.2022.02.002

NAFLD与肝细胞恶性转化相关研究新进展^*

周平, 姚登福, 姚敏

226001 江苏省南通市南通大学医学院免疫学系(周平,姚敏);附属医院临床医学研究中心(姚登福)

收稿日期:2021-11-12 出版日期:2022-03-10 发布日期:2022-03-15
通讯作者: 姚敏,E-mail:erbei@ntu.edu.cn
作者简介:周平,女,23岁,硕士研究生。主要从事炎症、免疫与肿瘤防治研究
基金资助:
*国家自然科学基金资助项目(编号:31872738);南通市重点科研专项(编号:MS12020021);南通大学医学院自然科学研究项目(编号:TDYX2021010)

Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases

Zhou Ping, Yao Dengfu, Yao Min

Institute of Immunology, Nantong University School of Medicine, Nantong 226001,Jiangsu Province, China

Received:2021-11-12 Online:2022-03-10 Published:2022-03-15

摘要/Abstract

关键词: 非酒精性脂肪性肝病, 线粒体损伤, 非编码RNA, 肝细胞恶性转化

Key words: Nonalcoholic fatty liver diseases, Mitochondria injury, Non-coding RNA, Hepatocyte malignant transformation

周平, 姚登福, 姚敏. NAFLD与肝细胞恶性转化相关研究新进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 157-160.

Zhou Ping, Yao Dengfu, Yao Min. Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2022, 25(2): 157-160.

[1] Huang DQ, El-Serag HB, Loomba R.Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2021,18(4):223-238.
[2] Zou ZY, Zeng J, Ren TY, et al. Efficacy of intragastric balloons in the markers of metabolic dysfunction-associated fatty liver disease: Results from meta-analyses. J Clin Transl Hepatol, 2021, 9(3):353-363.
[3] Bence KK, Birnbaum MJ.Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab, 2021, 50:101143.
[4] Prasun P, Ginevic I, Oishi K.Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. Transl Gastroenterol Hepatol, 2021,6:4.
[5] Choudhary NS, Duseja A.Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). Transl Gastroenterol Hepatol, 2021, 6:2. DOI:10.21037/tgh.2019.09.06
[6] Geh D, Manas DM, Reeves HL.Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr, 2021, 10(1): 59-75.
[7] Eguchi Y, Wong G, Lee IH, et al.Hepatocellular carcinoma and other complications of non- alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works. Hepatol Res, 2021, 51(1):19-30.
[8] Feng G, Li XP, Niu CY, et al. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Gene, 2020, 742: 144549.
[9] Jiang ZY, Zhou Y, Zhou L,et al. Identification of key genes and immune infiltrate in nonalcoholic steatohepatitis: A bioinformatic analysis. Biomed Res Int, 2021, 2021:7561645.
[10] Endo S, Matsunaga T, Nishinaka T.The role of AKR1B10 in physiology and patho- physiology. Metabolites, 2021,11(6):332.
[11] Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al.Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta- regression. Clin Gastroenterol Hepatol. 2021, S1542-3565(21)00505-X.
[12] Barrow F, Khan S, Wang H,et al. The emerging role of B cells in the pathogenesis of NAFLD. Hepatology, 2021[ahead of print].
[13] Khan O.Giles JR, McDonald S, et al. TOX transcriptionally and epigenetically programs CD8+T cell exhaustion. Nature, 2019,571:211–218.
[14] Pfister D, Núñez NG, Inyol R, et al. NASH limits anti-tumour surveillance in immuno-therapy-treated HCC. Nature, 2021,592(7854):450-456.
[15] Raza S, Rajak S, Upadhyay A, et al.Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed). 2021; 26:206-237.
[16] Ma C, Kesarwala AH, Eggert T, et al.NAFLD causes selective CD4 (+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 2016, 531(7593):253-257.
[17] Wang T, Sun G, Wang Y, et al.The immunoregulatory effects of CD8 T-cell-derived perforin on diet-induced nonalcoholic steatohepatitis. FASEB J, 2019, 33(7):8490-8503.
[18] Van Herck MA, Weyler J, Kwanten WJ, et al.The differential roles of T cells in non- alcoholic fatty liver disease and obesity. Front Immunol, 2019,10:82.
[19] Van Herck MA, Vonghia L, Kwanten WJ, et al.Adoptive cell transfer of regulatory T cells exacerbates hepatic steatosis in high-fat high-fructose diet-fed mice. Front Immunol, 2020, 11:1711.
[20] S＇widerska M, Jaroszewicz J, Stawicka A, et al. The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease. Clin Exp Hepatol, 2017, 3(3):127-134.
[21] He B, Wu L, Xie W, et al.The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice. BMC Immunol, 2017,18(1):33.
[22] Durand M, Coué M, Croyal M, et al.Changes in key mitochondrial lipids accompany mito- chondrial dysfunction and oxidative stress in NAFLD. Oxid Med Cell Longev, 2021, 2021: 9986299.
[23] Dabravolski SA, Bezsonov EE, Baig MS, et al.Mitochondrial mutations and genetic factors determining NAFLD risk. Int J Mol Sci, 2021, 22(9):4459.
[24] Ajaz S, McPhail MJ, Gnudi L, et al.Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion 2021,57:119-130.
[25] Meex RCR, Blaak EE.Mitochondrial dysfunction is a key pathway that links saturated fat intake to the development and progression of NAFLD. Mol Nutr Food Res, 2021, 65(1): e1900942.
[26] Xiao WC, Ren M, Can Zhang C, et al. Amelioration of nonalcoholic fatty liver disease by hepatic stimulator substance via preservation of carnitine palmitoyl transferase-1 activity. Am J Physiol Cell Physiol, 2015, 309(4):C215-227.
[27] Gu JJ, Yao M, Yang J, et al.Mitochondrial carnitine palmitoyl transferase-II inactivity aggravates lipid accumulation in rat hepatocarcinogenesis. World J Gastroenterol, 2017, 23 (2): 256-264.
[28] Xu D, Tian Y, Xia Q, et al.The cGAS-STING pathway: Novel perspectives in liver diseases. Front Immunol, 2021, 12:682736.
[29] Li A, Yi M, Qin S, et al. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol, 2019,12: 35.
[30] Longo M, Paolini E, Meroni M, et al.Remodeling of mitochondrial plasticity: The key switch from NAFLD/NASH to HCC. Int J Mol Sci, 2021, 22(8):4173.
[31] Giraud J, Saleh M.Host-microbiota interactions in liver inflammation and cancer. Cancers (Basel), 2021,13(17):4342.
[32] Wu L, Li J, Feng J, et al.Crosstalk between PPARs and gut microbiota in NAFLD. Biomed Pharmacother, 2021, 136:111255.

NAFLD与肝细胞恶性转化相关研究新进展^*

Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	侯文靖, 吴广明, 盖慧慧. 三七总皂苷对非酒精性脂肪性肝病小鼠肝组织脂质沉积及NO/iNOS/NF-κB通路的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 174-178.
[2]	陈凯, 居峰. 多烯磷脂酰胆碱联合扶正化瘀片治疗非酒精性脂肪性肝病患者肝脏超声脂肪变性评分变化^*[J]. 实用肝脏病杂志, 2022, 25(2): 219-222.
[3]	梁烨倍, 杨春光, 王昆凤, 胡秋明, 李妍辉, 罗琴, 陈浩, 郑亚雄, 余俊, 唐小英, 史华祥, 牛涛, 吴伟, 侯旭宏, 贾伟平. 云南省布朗族成人非酒精性脂肪性肝病流行特点研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 223-226.
[4]	李伟, 黄宇, 钟璟, 韦隽. 外周血PNPLA3 rs738409基因多态性与非酒精性脂肪性肝病遗传易感性研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 227-230.
[5]	莫超艳, 杨有强, 钟嫄, 肖友雪. 非酒精性脂肪性肝病合并2型糖尿病患者血清抵抗素和黄醇结合蛋白4水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 231-234.
[6]	王芳, 高晓霞, 汪庆强. 黄连解毒汤联合益生菌制剂对非酒精性脂肪性肝炎患者中医症候积分和肠道菌群平衡的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 235-238.
[7]	黄蝶, 田昊宇, 李异玲. 非酒精性脂肪性肝病血清标志物研究进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 297-300.
[8]	吕春卉, 李大炜, 王小洁, 康晓平, 韩宗晟, 朱允. 二甲双胍联合辛伐他汀治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J]. 实用肝脏病杂志, 2022, 25(1): 50-53.
[9]	任洁, 郝巧歆, 黄成河, 陈勋, 卢欣. 非酒精性脂肪性肝病合并T2DM患者肠道菌群结构变化研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 54-57.
[10]	顾雪香, 李祥玉, 单勤星. 柴胡皂苷a通过影响PPARα信号通路对非酒精性脂肪性肝病大鼠肝脂肪变的保护作用^*[J]. 实用肝脏病杂志, 2021, 24(6): 807-810.
[11]	贾坤, 苏建荣, 孙伟. 慢性丙型肝炎患者血清和外泌体LncRNA HEIH水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 823-826.
[12]	徐祥涛, 乔飞, 车军勇, 陆玮婷. 化浊通淤汤治疗非酒精性脂肪性肝病患者短期疗效研究[J]. 实用肝脏病杂志, 2021, 24(5): 701-704.
[13]	马上吉, 郑扬, 陈旭峰, 向正国, 吴琳. 老年非酒精性脂肪性肝病合并冠心病患者临床特点及危险因素分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 705-708.
[14]	张译之, 张晓慧, 陈煜. 非酒精性脂肪性肝病动物模型研究进展^*[J]. 实用肝脏病杂志, 2021, 24(5): 761-764.
[15]	张佳, 晋明渊, 杜艳云, 胡秀娟, 王烈姣. NAFLD合并Hp感染患者清除治疗前后血清细胞因子水平变化^*[J]. 实用肝脏病杂志, 2021, 24(4): 500-503.